Clarity Pharmaceuticals (ASX:CU6) - Executive Chairman, Dr Alan Taylor
Executive Chairman, Dr Alan Taylor
Source: Clarity Pharmaceuticals
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clarity Pharmaceuticals (CU6) has received a research and development (R&D) tax refund of more than $3.26 million for FY21
  • The refund is part of The Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity in the radiopharmaceutical field
  • The R&D tax incentive is a program by the Australian Federal Government the encourages companies to engage and invest in R&D activities
  • Clarity will use the $3.26 million to further finance the development of its Targeted Copper Theranostics (TCT) platform of products for various cancer indications
  • Shares in Clarity are trading up 2.84 per cent to 72.5 cents

Clarity Pharmaceuticals (CU6) has received a research and development (R&D) tax refund of $3,262,861 for FY21.

The refund is part of The Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity in the radiopharmaceutical field.

The R&D tax incentive is a program by the Australian Federal Government to encourage companies to engage and invest in R&D activities.

Clarity will use the $3.26 million to further finance the development of its Targeted Copper Theranostics (TCT) platform of products for various cancer indications.

“The R&D tax incentive provides Clarity with a valuable source of non-dilutive funding to assist us with investment in the development and validation of the TCT platform,” Executive Chairman Dr Alan Taylor said.

“Clarity continues to progress our portfolio of next-generation radiopharmaceutical products through clinical trials in the US and Australia in pursuit of our ultimate goal of improving treatment outcomes for children and adults with cancer.”

Shares in Clarity were trading up 2.84 per cent to 72.5 cents at 2:40 pm AEDT.

CU6 by the numbers
More From The Market Herald
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus

Starpharma’s (ASX:SPL) antiviral agent achieves up to 99.7 per cent reduction in viral activity against two…

" Culpeo Minerals (ASX:CPO) identifies new targets Lana Corina

Culpeo Minerals (ASX:CPO) has identified new geophysical targets from a recently completed magnetic survey at its…

" iTech Minerals (ASX:ITM) intersects REE in first drill holes at Ethiopia prospect

iTech Minerals (ASX:ITM) intersects intervals of rare earth elements (REE) in the first drill holes at…

" Anteotech (ASX:ADO) soars on fresh COVID-19 RAT regulatory approval in Europe

Anteotech (ASX:ADO) has successfully registered its updated EuGeni COVID-19 Rapid Antigen Test (RAT) in Europe under…